Bivalent human hookworm vaccine - Sabin

Drug Profile

Bivalent human hookworm vaccine - Sabin

Alternative Names: Na-APR-1 (M74)/Alhydrogel® and Na-GST-1/Alhydrogel® bivalent hookworm vaccine

Latest Information Update: 08 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sabin Vaccine Institute
  • Developer Baylor College of Medicine; Johns Hopkins University; Sabin Vaccine Institute; The George Washington University of Washington, D.C.; University of California at San Francisco
  • Class Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hookworm infections

Most Recent Events

  • 08 Jun 2017 Baylor College of Medicine plans a phase II trial for Hookworm infections in USA (NCT03172975)
  • 18 May 2017 Phase-I clinical trials in Hookworm infections (Prevention, In children) in Gabon (IM) (NCT02839161)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top